首页> 外文期刊>International archives of occupational and environmental health: Internationales Archiv fur Arbeits- und Umweltmedizin >Is the early cyclosporine A level predictive of the outcome of immunosuppressive therapy in severe aplastic anemia?
【24h】

Is the early cyclosporine A level predictive of the outcome of immunosuppressive therapy in severe aplastic anemia?

机译:早期环孢素A水平是否可预示严重再生障碍性贫血中免疫抑制治疗的结果?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Immunosuppressive therapy (IST) has provided an alternative treatment option for cure of aplastic anemia patients who cannot receive bone marrow transplantation. Although there have been many recent studies on the efficacy of antithymoglobulin (ATG) combined with cyclosporine A (CsA), there is no data on the correlation between the variability of CsA levels and the response to IST. Therefore, we retrospectively assessed the factors associated with IST efficacy in patients with acquired severe aplastic anemia (SAA). Sixty-six patients were treated with ATG combined with CsA for 6 months. In the response group, the CsA levels were increased rapidly to more than 200 ng/mL within the first 2 wk after starting the IST. However, the non-response group had a pattern of slower increase of the CsA levels. The CsA levels, during the first and second week of treatment with IST, were significantly different in the responders and non-responders. The factors predictive of response to IST and survival were analyzed. The univariate analysis showed that a younger age at the initiation of IST, a high absolute neutrophil count prior to starting IST, a short interval between the diagnosis and initiation of IST, and high CsA levels during the first and second week of IST treatment were positively associated with the response rate and overall survival. The multivariate analysis showed that these four factors were independent factors associated with a longer patient survival. A high response rate was associated with a short interval between diagnosis and initiation of IST as well as high CsA levels during the first and second week of IST. Therefore, early intensification of CsA levels might improve patient outcome.
机译:免疫抑制疗法(IST)为治愈无法接受骨髓移植的再生障碍性贫血患者提供了另一种治疗选择。尽管最近有许多关于抗胸腺球蛋白(ATG)联合环孢菌素A(CsA)疗效的研究,但尚无关于CsA水平变异性和对IST反应之间相关性的数据。因此,我们回顾性评估了获得性严重再生障碍性贫血(SAA)患者与IST疗效相关的因素。 66例患者接受ATG联合CsA治疗6个月。在反应组中,在开始IST后的最初2周内,CsA水平迅速升高至200 ng / mL以上。但是,无反应组的CsA水平升高的速度较慢。在接受IST治疗的第一周和第二周,CsA水平在有反应者和无反应者中显着不同。分析了预测对IST反应和生存的因素。单因素分析显示,在开始IST时年龄较小,在开始IST之前中性粒细胞绝对计数高,在IST诊断和开始之间的时间间隔短以及在IST治疗的第一周和第二周内CsA水平高与反应率和整体生存率相关。多元分析表明,这四个因素是与更长患者生存期相关的独立因素。高响应率与IST诊断和开始之间的间隔时间短以及IST的第一周和第二周的CsA水平高有关。因此,尽早加强CsA水平可改善患者预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号